Showing results (11-20 of 41) with videos related to

Sort By:
Pageof 5
Therapeutics and Clinical Risk Management|January 19, 2017
A Phase II single-arm trial of palonosetron for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in malignant glioma patients receiving multidose irinotecan in combination with bevacizumabMary Lou Affronti, Sarah Woodring, Katherine B Peters, et al.
Controlled Clinical Trials|December 4, 2003
The role of the data coordinating center in the DIG trialWilliam O Williford, Joseph F Collins, Anne Horney, et al.
The Oncologist|May 31, 2015
Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable GlioblastomaKatherine B Peters, Emil Lou, Annick Desjardins, et al.
The Oncologist|November 15, 2017
Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant GliomaAshley Ghiaseddin, David Reardon, Woody Massey, et al.
Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco|August 18, 2011
Selegiline transdermal system (STS) as an aid for smoking cessationRoberta Kahn, Liza Gorgon, Karen Jones, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 29, 2021
Increasing physical activity in Cancer Survivors through a Text-messaging Exercise motivation Program (ICanSTEP)Bridget F Koontz, Erica Levine, Frances McSherry, et al.
Journal of Neuro-Oncology|August 14, 2014
Impact of health-related quality of life and fatigue on survival of recurrent high-grade glioma patientsKatherine B Peters, Miranda J West, Whitney E Hornsby, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 9, 2016
Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ)Mary Lou Affronti, Sarah Woodring, Karen Allen, et al.
The Oncologist|April 19, 2018
Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant GliomaMary Lou Affronti, Jennifer Gamboa Jackman, Frances McSherry, et al.
Health Science Reports|May 4, 2019
Single-institution retrospective review of patients with recurrent glioblastoma treated with bevacizumab in clinical practiceAnnick Desjardins, James E Herndon, Frances McSherry, et al.
Pageof 5